DK2326638T5 - Diazepin- og diazocan-forbindelser som mc4-agonister - Google Patents
Diazepin- og diazocan-forbindelser som mc4-agonisterInfo
- Publication number
- DK2326638T5 DK2326638T5 DK09786755.0T DK09786755T DK2326638T5 DK 2326638 T5 DK2326638 T5 DK 2326638T5 DK 09786755 T DK09786755 T DK 09786755T DK 2326638 T5 DK2326638 T5 DK 2326638T5
- Authority
- DK
- Denmark
- Prior art keywords
- diazocan
- diazepin
- agonists
- compounds
- diazocan compounds
- Prior art date
Links
- 229940124757 MC-4 agonist Drugs 0.000 title 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 title 1
- KJGHYQZXEYTDSW-UHFFFAOYSA-N diazocane Chemical class C1CCCNNCC1 KJGHYQZXEYTDSW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8653008P | 2008-08-06 | 2008-08-06 | |
| PCT/IB2009/053317 WO2010015972A1 (en) | 2008-08-06 | 2009-07-30 | Diazepine and diazocane compounds as mc4 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2326638T3 DK2326638T3 (da) | 2013-08-05 |
| DK2326638T5 true DK2326638T5 (da) | 2014-01-13 |
Family
ID=41226202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09786755.0T DK2326638T5 (da) | 2008-08-06 | 2009-07-30 | Diazepin- og diazocan-forbindelser som mc4-agonister |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8592403B2 (enExample) |
| EP (1) | EP2326638B9 (enExample) |
| JP (1) | JP5530438B2 (enExample) |
| KR (1) | KR101280786B1 (enExample) |
| CN (1) | CN102171206B (enExample) |
| AU (1) | AU2009278838B2 (enExample) |
| CA (1) | CA2731897C (enExample) |
| DK (1) | DK2326638T5 (enExample) |
| ES (1) | ES2421920T3 (enExample) |
| IL (1) | IL210703A (enExample) |
| MX (1) | MX2011001405A (enExample) |
| WO (1) | WO2010015972A1 (enExample) |
| ZA (1) | ZA201100374B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2512778Y2 (ja) | 1990-06-19 | 1996-10-02 | 株式会社荏原製作所 | 全速待機運転ポンプ |
| ES2402581T3 (es) | 2006-02-23 | 2013-05-06 | Pfizer Limited | Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4 |
| CN102464623B (zh) * | 2010-11-19 | 2015-04-29 | 上海药明康德新药开发有限公司 | 1,4-二氮杂环辛烷-6-甲酸酯衍生物的制备方法 |
| SMT202100734T1 (it) | 2011-12-29 | 2022-03-21 | Rhythm Pharmaceuticals Inc | Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti |
| CN105209025B (zh) * | 2013-04-11 | 2019-06-18 | 西梯茜生命工学股份有限公司 | 包括聚乙二醇类聚合物和/或乙烯基吡咯烷酮类聚合物作为分散稳定剂的含他达拉非游离碱的膜剂形式 |
| US11116769B2 (en) * | 2013-04-11 | 2021-09-14 | Ctc Bio, Inc. | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer |
| KR20180032585A (ko) * | 2015-08-04 | 2018-03-30 | 아스테라스 세이야쿠 가부시키가이샤 | 피페라진 유도체 |
| US10960046B2 (en) | 2015-09-30 | 2021-03-30 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor pathway-associated disorders |
| WO2019195756A1 (en) | 2018-04-06 | 2019-10-10 | Rhythm Pharmaceuticals, Inc. | Compositions for treating kidney disease |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH507249A (de) | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
| GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| CA2098167C (en) | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
| EP0703905A1 (en) * | 1993-06-18 | 1996-04-03 | Merck & Co. Inc. | Inhibitors of farnesyl-protein transferase |
| TW381025B (en) | 1993-08-05 | 2000-02-01 | Hoffmann La Roche | Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| DE4435477A1 (de) | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
| US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
| US5929075A (en) | 1994-10-27 | 1999-07-27 | Janssen Pharmaceutica, N.V. | Apolipoprotein-B synthesis inhibitors |
| WO1997017973A1 (en) * | 1995-11-13 | 1997-05-22 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| CA2260872A1 (en) * | 1996-08-14 | 1998-02-19 | Elaine Sophie Elizabeth Stokes | Substituted pyrimidine derivatives and their pharmaceutical use |
| EP0923545A1 (en) * | 1996-08-17 | 1999-06-23 | Zeneca Limited | 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors |
| US5929077A (en) | 1996-11-08 | 1999-07-27 | Leftheris; Katerina | Thioproline-containing inhibitors of farnesyl protein transferase |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| KR100652994B1 (ko) | 1998-09-11 | 2006-11-30 | 아방티 파르마 소시에테 아노님 | 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제 |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| RU2275207C2 (ru) | 2000-12-14 | 2006-04-27 | Амилин Фармасьютикалз, Инк. | Способ снижения доступности питательного вещества, способ подавления аппетита |
| SK286917B6 (sk) | 2001-02-28 | 2009-07-06 | Merck & Co., Inc. | 4-Substituované N-acylované deriváty piperidínu, farmaceutický prípravok s ich obsahom a ich použitie |
| ES2272703T3 (es) | 2001-02-28 | 2007-05-01 | MERCK & CO., INC. | Derivados de piperidina acilados como agonistas de receptor de melanocortina-4. |
| DE60202270T2 (de) | 2001-03-22 | 2005-05-19 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazolderivate mit cb1-antagonistischer wirkung |
| CA2461454A1 (en) | 2001-09-24 | 2003-04-03 | Oregon Health And Science University | Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior |
| EP1482794A1 (en) | 2002-03-06 | 2004-12-08 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
| JP4202319B2 (ja) | 2002-07-29 | 2008-12-24 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ベンゾジオキソール |
| EP1558252B1 (en) | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| MY134457A (en) | 2002-11-22 | 2007-12-31 | Merck & Co Inc | Substituted amides |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| US7151097B2 (en) | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| DE602005005080T2 (de) * | 2004-10-15 | 2009-02-26 | Glaxo Group Ltd., Greenford | Pyrrolidinderivate als histaminrezeptor-liganden |
| WO2006104008A1 (ja) * | 2005-03-25 | 2006-10-05 | Kissei Pharmaceutical Co., Ltd. | ウレア誘導体、それを含有する医薬組成物およびそれらの医薬用途 |
| US20080269233A1 (en) | 2005-08-04 | 2008-10-30 | Mark David Andrews | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds |
-
2009
- 2009-07-30 MX MX2011001405A patent/MX2011001405A/es active IP Right Grant
- 2009-07-30 CN CN200980139321.7A patent/CN102171206B/zh not_active Expired - Fee Related
- 2009-07-30 AU AU2009278838A patent/AU2009278838B2/en not_active Ceased
- 2009-07-30 WO PCT/IB2009/053317 patent/WO2010015972A1/en not_active Ceased
- 2009-07-30 EP EP09786755.0A patent/EP2326638B9/en not_active Not-in-force
- 2009-07-30 JP JP2011521666A patent/JP5530438B2/ja not_active Expired - Fee Related
- 2009-07-30 DK DK09786755.0T patent/DK2326638T5/da active
- 2009-07-30 US US13/057,319 patent/US8592403B2/en not_active Expired - Fee Related
- 2009-07-30 ES ES09786755T patent/ES2421920T3/es active Active
- 2009-07-30 CA CA2731897A patent/CA2731897C/en not_active Expired - Fee Related
- 2009-07-30 KR KR1020117005275A patent/KR101280786B1/ko not_active Expired - Fee Related
-
2011
- 2011-01-14 ZA ZA2011/00374A patent/ZA201100374B/en unknown
- 2011-01-17 IL IL210703A patent/IL210703A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL210703A (en) | 2015-01-29 |
| CN102171206B (zh) | 2014-06-25 |
| IL210703A0 (en) | 2011-03-31 |
| ZA201100374B (en) | 2012-03-28 |
| JP2011529959A (ja) | 2011-12-15 |
| WO2010015972A1 (en) | 2010-02-11 |
| ES2421920T3 (es) | 2013-09-06 |
| DK2326638T3 (da) | 2013-08-05 |
| EP2326638A1 (en) | 2011-06-01 |
| CA2731897C (en) | 2013-07-02 |
| EP2326638B1 (en) | 2013-06-19 |
| MX2011001405A (es) | 2011-03-21 |
| EP2326638B9 (en) | 2013-11-13 |
| CA2731897A1 (en) | 2010-02-11 |
| JP5530438B2 (ja) | 2014-06-25 |
| HK1158619A1 (en) | 2012-07-20 |
| US8592403B2 (en) | 2013-11-26 |
| KR101280786B1 (ko) | 2013-07-05 |
| CN102171206A (zh) | 2011-08-31 |
| AU2009278838B2 (en) | 2013-07-25 |
| KR20110039488A (ko) | 2011-04-18 |
| AU2009278838A1 (en) | 2010-02-11 |
| US20110136814A1 (en) | 2011-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2326638T5 (da) | Diazepin- og diazocan-forbindelser som mc4-agonister | |
| DE602008002756D1 (de) | Bauzusammensetzung | |
| BRPI0906749A2 (pt) | Composição | |
| BRPI0913808A2 (pt) | composição | |
| EP2256030A4 (en) | AIRCRAFT ASSEMBLY | |
| BRPI0910515A2 (pt) | composição líquida | |
| EP2381760A4 (en) | CORN PROTEIN COMPOSITION | |
| PT2813570T (pt) | Resumo | |
| BRPI0917231A2 (pt) | composição | |
| HRP20180718T1 (hr) | Oligopeptidni spojevi i njihova upotreba | |
| BRPI0813775A2 (pt) | Composição | |
| EP2275504A4 (en) | COATING AGENT COMPOSITION | |
| HRP20181851T1 (hr) | Višeslojna folija | |
| ATE528048T1 (de) | Schweisshemmende/desodorierende zusammensetzung | |
| FIC20240018I1 (fi) | Vamoroloni | |
| BRPI0807911A2 (pt) | Agonistas de alfa2c adrenorreceptor | |
| BRPI0815251A2 (pt) | Composição descolorante estabilizada | |
| BRPI0811274A2 (pt) | Composição | |
| BRPI0810557A2 (pt) | composição | |
| BRPI0920287A2 (pt) | composição para lavagem de louças | |
| BRPI0918344A2 (pt) | composição catalítica | |
| EP2197828A4 (en) | FULLERENE MULTI-ADDUCT COMPOSITIONS | |
| BRPI0811002A2 (pt) | Composição biofertilizante | |
| BRPI0820960A2 (pt) | composição | |
| EP2357204A4 (en) | COMPOSITION |